Last $10.15 USD
Change Today -0.04 / -0.39%
Volume 34.2K
ICAD On Other Exchanges
Symbol
Exchange
Stuttgart
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

icad inc (ICAD) Snapshot

Open
$10.15
Previous Close
$10.19
Day High
$10.26
Day Low
$9.84
52 Week High
01/16/14 - $14.11
52 Week Low
06/23/14 - $5.94
Market Cap
157.8M
Average Volume 10 Days
24.0K
EPS TTM
$-0.35
Shares Outstanding
15.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ICAD INC (ICAD)

icad inc (ICAD) Related Bloomberg News

View More Bloomberg News

icad inc (ICAD) Related Businessweek News

No Related Businessweek News Found

icad inc (ICAD) Details

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. The company operates in two segments, Cancer Detection and Cancer Therapy. It offers electronic brachytherapy products (eBx), including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, and non-melanoma skin cancer, as well as for the treatment of other cancers or conditions where radiation therapy is indicated, including intraoperative radiation therapy. The company also provides digital and magnetic resonance imaging (MRI) computer-aided detection (CAD) products, such as SecondLook systems that detect and identify suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer’s network that receives patient studies from the imaging modality, performs CAD analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, it offers advanced image analysis and workflow solutions in MRI imaging; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. Further, the company provides film based products, such as TotalLook MammoAdvantage system, which is a second generation mammography specific digitizer that converts prior mammography films to digital images. iCAD, Inc. primarily serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses. The company sells its products directly, as well as through various original equipment manufacturer partners, distributors, and resellers worldwide. It has strategic partnership agreement with Invivo Corporation. The company was founded in 1984 and is headquartered in Nashua, New Hampshire.

102 Employees
Last Reported Date: 03/3/14
Founded in 1984

icad inc (ICAD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $412.4K
Chief Operating Officer
Total Annual Compensation: $328.6K
Senior Vice President of Marketing and Strate...
Total Annual Compensation: $253.6K
Compensation as of Fiscal Year 2013.

icad inc (ICAD) Key Developments

iCAD, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Second Half of 2014

iCAD, Inc. Announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $12,572,000 against $8,290,000 a year ago. Gain from operations was $926,000 against loss from operations of $354,000 a year ago. Net income was $274,000 against net loss of $589,000 a year ago. Basic and diluted earnings per share were $0.02 against basic and diluted loss per share of $0.05 a year ago. Non GAAP adjusted EBITDA was $2,554,000 against $545,000 a year ago. Non GAAP adjusted net income was $590,000 against non- GAAP adjusted net loss of $1,213,000 a year ago. Non GAAP adjusted net earnings per share was $0.04 against non-GAAP adjusted net loss per share of $0.11 a year ago. For the nine months, the company reported total revenues of $30,759,000 against $23,932,000 a year ago. Gain from operations was $300,000 against loss from operations of $1,155,000 a year ago. Net loss was $913,000 against $3,198,000 a year ago. Basic and diluted loss per share was $0.07 against $0.30 a year ago. Net cash used for operating activities was $148,000 against $3,183,000 a year ago. Additions to property and equipment wads $630,000 against $510,000 a year ago. Non GAAP adjusted EBITDA was $3,918,000 against $1,571,000 a year ago. Non GAAP adjusted net loss was $1,325,000 against $3,682,000 a year ago. Non GAAP adjusted net loss per share was $0.10 against $0.34 a year ago. The company increasing financial guidance for the second half of 2014 and now expects revenue in the second half of 2014 to be in the range of $25.5 million to $26 million and an adjusted EBITDA margin in the 18% to 22% range. This compares with previous guidance for revenue in the second half of 2014 between $23 million to $25 million and an adjusted EBITDA margin in the range of 10% to 15%.

iCAD, Inc. to Report Q3, 2014 Results on Oct 28, 2014

iCAD, Inc. announced that they will report Q3, 2014 results at 5:00 PM, Eastern Standard Time on Oct 28, 2014

iCAD, Inc., Q3 2014 Earnings Call, Oct 28, 2014

iCAD, Inc., Q3 2014 Earnings Call, Oct 28, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICAD:US $10.15 USD -0.04

ICAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $26.48 USD -0.07
Merge Healthcare Inc $3.18 USD -0.07
View Industry Companies
 

Industry Analysis

ICAD

Industry Average

Valuation ICAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICAD INC, please visit www.icadmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.